Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645364 | PMC |
| http://dx.doi.org/10.4103/0019-5049.167478 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Complexities of Management of Atypical Ventricular Fibrillation Storm in a Young Patient With TANGO2.
Case Rep Pediatr
December 2024
Paediatric Cardiac Anaesthetic Department, Bristol Royal Hospital for Children, Upper Maudlin Street, Bristol BS2 8BJ, UK.
TANGO2 deficiency disorder, a rare autosomal recessive genetic disorder characterised by biallelic loss-of-function variants in the TANGO2 gene, was first described in 2016. This disorder involves the transport and Golgi organisation homologue, impacting Golgi membrane redistribution into the endoplasmic reticulum. Clinically, affected individuals exhibit a multiorgan phenotype, with prominent neurological manifestations such as developmental delay and regression.
View Article and Find Full Text PDFLong-Term Outcomes of Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Use Among Patients on Maintenance Dialysis.
Heart Rhythm
November 2024
Duke Clinical Research Institute, Durham, North Carolina; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
Background: Despite an elevated risk of sudden cardiac death among dialysis patients, implantable cardioverter defibrillators (ICDs) have not been shown to improve mortality and are associated with high complication rates. Subcutaneous (S-)ICDs may reduce the risk of complications for eligible dialysis patients, but safety and benefits vs transvenous (TV-ICDs are unknown.
Objective: To compare long-term outcomes between dialysis patients receiving S-ICD vs TV-ICDs.
A Patch Wearable Cardioverter-Defibrillator for Patients at Risk of Sudden Cardiac Arrest.
J Am Coll Cardiol
August 2024
Baylor Scott and White Research Institute, Dallas, Texas, USA; Department of Medicine, University of Mississippi, Jackson, Mississippi, USA. Electronic address:
Background: For many patients, sudden cardiac arrest (SCA) risk is elevated temporarily. Wearable cardioverter-defibrillators (WCDs) can monitor and treat SCA during these temporary periods. Traditional WCDs can be uncomfortable, require frequent maintenance, and cannot be used when showering, resulting in poor compliance and avoidable SCA deaths.
View Article and Find Full Text PDFArticle Synopsis
- Aficamten is a new drug that helps reduce heart issues in patients with obstructive hypertrophic cardiomyopathy by targeting heart muscle contractility and maintaining safe blood flow levels.
- * In a clinical trial involving 282 patients, those receiving aficamten were able to maintain effective heart function with minimal side effects, including a stable reduction in heart muscle contraction without significant adverse events.
- * The findings suggest that using a tailored dosing strategy for aficamten is effective and safe, improving cardiovascular health without worsening conditions like heart failure.
Novel gas mixture combined with an auto-transfusion tourniquet enhances cerebral O transport and hemodynamic indices in CPR swine. Part B - A pilot experimental study.
Resusc Plus
September 2024
Université Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France.
Objectives: The cognitive outcome of CPR is poor. This study aims to evaluate if enhancing blood flow to the brain and oxygen dissociation from the hemoglobin improve cerebral O transport during CPR in cardiac arrest swine.
Methods: Standard swine-CPR model of induced VF and recovery was treated with an auto-transfusion tourniquet (A-TT®; HemaShock® (HS) Oneg HaKarmel Ltd.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!